In a 24 h cancer-cell study, BAY 11-7082 enhanced the effect of arsenic trioxide on MTT viability in U87 and OVCAR-3 cells, but did not enhance it in PANC-1 cells. U87 combination analysis supported synergy; the reported combination index was 0.260 for 7.5 μM BAY 11-7082 plus 1 μM arsenic trioxide. The response was model-dependent and does not establish a selective NF-κB mechanism. [2]
Inhibition of ubiquitin loading onto E2 enzymes
Biochemical assay · Reconstituted human UBE1 with Ubc13 or UbcH7 and ubiquitin [1]
BAY 11-7082 blocked ubiquitin loading onto Ubc13 and UbcH7, while ubiquitin loading onto UBE1 remained detectable. Minus-MgATP and drug-free reactions provide assay controls. These gel endpoints are not IC50 measurements.
Literature-Reported Treatment Conditions
- Treatment concentration
- 0.5, 1, 2, 4, 8 and 16 μM; 0 μM controls
- Exposure duration
- Figure 5 caption: 60 min preincubation. Shared E1/E2 assay method: 45 min at 21°C, then 10 min at 30°C after MgATP addition.
- Method
- Cell-free ubiquitin-loading assay; nonreducing SDS/PAGE and Coomassie staining
- Vehicle
- DMSO; matched DMSO control specified in the assay method
- Reported limits
- Preincubation duration differs between Figure 5 caption and shared methods (60 versus 45 min); unresolved. No IC50 or replicate n is provided in the selected caption.
Methods and source locations
Compound reported in the paper: BAY 11-7082; Compound label in the paper: Reported BAY 11-7082; catalog synonym of Bay 11-7821
Compound-level research applicability only; no salt conversion or validation of the current Adooq lot, purity or stereochemical composition.
Figure 5A–C and caption; Experimental Materials and E1/E2 ubiquitin-loading assays
Ubc13–ubiquitin and UbcH7–ubiquitin conjugates versus UBE1–ubiquitin control: SDS/PAGE, Coomassie stain — Figure 5A–C; Experimental: E1 and E2 ubiquitin-loading assays
Suppression of IL-1-induced canonical NF-κB pathway signaling
Cell-based study · Human IL-1 receptor-expressing HEK-293 cells [1]
BAY 11-7082 reduced IL-1β-induced IKKβ activation-loop phosphorylation and p105 phosphorylation and prevented IκBα degradation. The experiment measures cellular pathway activation, not direct inhibition of purified IKK.
Literature-Reported Treatment Conditions
- Treatment concentration
- 0, 2, 5, 10 and 15 μM
- Exposure duration
- 1 h pretreatment followed by 15 min IL-1β stimulation
- Method
- Immunoblotting after stimulation with 0.5 ng/ml IL-1β
- Co-treatment
- IL-1β is the assay stimulus, not a second therapeutic agent.
- Reported limits
- Vehicle concentration and biological replicate n are not specified in the selected activation-assay caption. Duplicate lanes are not assumed to be independent experiments.
Methods and source locations
Compound reported in the paper: BAY 11-7082; Compound label in the paper: Reported BAY 11-7082; catalog synonym of Bay 11-7821
Compound-level research applicability only; no salt conversion or validation of the current Adooq lot, purity or stereochemical composition.
Figure 2B and caption; Experimental Materials, cell stimulation/lysis and immunoblotting
Phospho-IKKβ, phospho-p105 and IκBα abundance relative to IL-1β-only and unstimulated controls: Immunoblotting; GAPDH loading control — Figure 2B and caption; Experimental: cell stimulation and immunoblotting
Cell-type-dependent interaction with arsenic trioxide
Cell-based study · U87 glioblastoma, OVCAR-3 ovarian carcinoma and PANC-1 pancreatic cancer cells [2]
Combination treatment lowered the MTT viability signal relative to arsenic trioxide alone in U87 and OVCAR-3 cells; no enhancement was reported in PANC-1 cells. U87 drug-interaction analysis supported synergy. MTT measures metabolic viability and does not itself establish apoptosis or a specific molecular target.
Literature-Reported Treatment Conditions
- Treatment concentration
- BAY 11-7082 alone: 0, 2.5, 5, 7.5 and 10 μM. Combination: 7.5 or 10 μM BAY 11-7082 with 0–6 μM arsenic trioxide.
- Exposure duration
- 24 h drug exposure
- Method
- MTT viability assay and U87 Chou–Talalay combination analysis
- Vehicle
- DMSO; final DMSO did not exceed 0.1% [v/v]. Statistical methods specify vehicle-treated controls.
- Co-treatment
- Arsenic trioxide, 0, 1, 2, 3, 4, 5 and 6 μM; single-agent series also tested.
- Reported limits
- Figure 1b displays each zero-ATO condition near 100%, whereas Figure 1a shows a BAY-only viability decrease; the normalization relationship is not explained in the inspected text. Absolute cross-panel effects and single-agent EC50 values are not extracted.
Methods and source locations
Compound reported in the paper: BAY 11-7082; Compound label in the paper: Reported BAY 11-7082; catalog synonym of Bay 11-7821
Compound-level research applicability only; no salt conversion or validation of the current Adooq lot, purity or stereochemical composition.
Materials and Methods: cell lines/drug treatment, viability, combination analysis, statistics; Figures 1–2; Table 2
24 h MTT viability across the three cell models: MTT; Figure 1 values reported as mean±SD of three independent experiments; methods describe triplicate evaluation — Figure 1a–b; first Results subsection; Statistical analysis
U87 interaction of 7.5 μM BAY 11-7082 with 1 μM arsenic trioxide: Chou–Talalay/CalcuSyn; CI < 1 defined as synergy. No uncertainty or row-specific n reported in Table 2. — Table 2, first data row; Drug combination analysis; Figure 2c